A Schweizer, A Couturier, JE Foley, S Dejager - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 89 - Related articles - BL Direct - All 4 versions
- ►adisonline.com [PDF] J Waugh, GM Keating, GL Plosker, S … - Drugs, 2006 - ingentaconnect.com 0012-6667/06/0001-0085/$44.95/0 2006 Adis Data Information BV. All rights
reserved. ... A Review of its Use in Type 2 Diabetes Mellitus ... John Waugh,
Gillian M. Keating, Greg L. Plosker, Stephanie Easthope and Dean M. Robinson Cited by 64 - Related articles - BL Direct - All 7 versions
JWF Elte, JF Blickle - European Journal of Internal Medicine, 2007 - Elsevier Thiazolidinediones (TZD), or glitazones, represent a new generation of
antidiabetic drugs that have recently been introduced in Europe. They improve
insulin resistance, one of the key anomalies involved in the pathogenesis ... Cited by 25 - Related articles - All 11 versions
- ►diabetesjournals.org DM Kendall - Diabetes Care, 2006 - Am Diabetes Assoc Editor's note: This commentary was originally solicited as part of a
Point-Counterpoint feature, but the author of the Counterpoint failed to provide
the promised manuscript. Thiazolidinediones (TZDs), or “glitazones,” ... Cited by 21 - Related articles - All 4 versions
CV Rizos, EN Liberopoulos, DP Mikhailidis, … - Expert Opin. Pharmacother., 2008 - informahealthcare.com Background: Insulin resistance and hyperglycemia characterize type 2 diabetes
mellitus. Type 2 diabetes mellitus is usually accompanied by concomitant
disorders, such as dyslipidemia, hypertension and atherosclerosis. ... Cited by 18 - Related articles - BL Direct - All 6 versions
M Virally, JF Blicklé, J Girard, S Halimi, D … - Diabetes and Metabolism, 2007 - Elsevier In France, prevalence of drug-treated diabetes reached 3.60% in 2005, with 92%
of type 2 diabetic patients. In 2007, there are probably nearly 3 000 000
diagnosed or undiagnosed diabetic patients. Ageing of the population and ... Cited by 18 - Related articles - BL Direct - All 2 versions
IW Campbell, S Mariz - Diabetes research and clinical practice, 2007 - Elsevier Progressive β-cell dysfunction and β-cell failure are fundamental pathogenic
features of type 2 diabetes. Ultimately, the development and continued
progression of diabetes is a consequence of the failure of the β-cell to ... Cited by 13 - Related articles - All 11 versions
A Pfützner, T Forst - Expert Opin. Pharmacother., 2006 - Informa Pharma Science Pioglitazone is an antidiabetic drug known to decrease peripheral, hepatic and
vascular insulin resistance by the stimulation of PPARγ. In clinical trials,
pioglitazone as monotherapy or in combination with other oral antidiabetic ... Cited by 11 - Related articles - BL Direct - All 5 versions
